Abstract
Introduction: Malignant mixed Müllerian tumors (MMMT), also known as carcinosarcomas, are rare and highly aggressive neoplasms of the uterus, accounting for less than 5% of all uterine malignancies. These tumors are biphasic, comprising both carcinomatous (epithelial) and sarcomatous (mesenchymal) components, and are typically associated with poor prognoses due to their rapid progression and high metastatic potential.
In this report, we present a unique case of noninvasive polypoid MMMT of the uterus, highlighting its clinical presentation, diagnostic challenges, and management. We also provide a comprehensive literature review, which enriches our understanding of this case within the broader context of uterine carcinosarcomas.
Results: This is the first documented case in English literature of a polypoid uterine carcinosarcoma without endometrial infiltration. It is significant because it adds to the limited literature on noninvasive polypoid MMMTs, typically aggressive and diagnosed at advanced stages. Uterine carcinosarcomas are generally aggressive, with most cases diagnosed at advanced stages.
Conclusion: Uterine carcinosarcomas are indeed rare, aggressive, and rapidly progressing neoplasms with poor prognoses. It is crucial to include carcinosarcomas in the differential diagnosis of high-grade uterine neoplasms, especially for polypoid tumors. This inclusion is not just essential, but it is the key to ensuring accurate and timely diagnosis, underscoring the significant role of medical professionals in this process.
References
1. Bing, Z., Pasha, T., Wang, P., & Zhang, P. J. (2011). Malignant Mixed Mullerian Tumor: An Immunohistochemical Study. Pathology Research International, 2012(1), 569609. https://doi.org/10.1155/2012/569609
Curtis, R. E., Freedman, D. M., Sherman, M. E., & Fraumeni, J. F., Jr (2004). Risk of malignant mixed mullerian tumors after tamoxifen therapy for breast cancer. Journal of the National Cancer Institute, 96(1), 70–74. https://doi.org/10.1093/jnci/djh007
McCluggage W. G. (2002). Malignant biphasic uterine tumours: carcinosarcomas or metaplastic carcinomas? Journal of Clinical Pathology, 55(5), 321–325. https://doi.org/10.1136/jcp.55.5.321
Gotoh, O., Sugiyama, Y., Takazawa, Y., Kato, K., Tanaka, N., Omatsu, K., Takeshima, N., Nomura, H., Hasegawa, K., Fujiwara, K., Taki, M., Matsumura, N., Noda, T., & Mori, S. (2019). Clinically relevant molecular subtypes and genomic alteration-independent differentiation in gynecologic carcinosarcoma. Nature communications, 10(1), 4965. https://doi.org/10.1038/s41467-019-12985-x
Morgan, Emmanuel D.a; Okecha, Tonyb; Yahaya, James J.c,; Othieno, Emmanuela,d. Malignant mixed mullerian tumor: A case report about a uterine Tumor's case. IJS Open 43(): p 100493, June 2022. | DOI: https://doi.org/10.1016/j.ijso.2022.100493
Kanthan, R., & Senger, J. L. (2011). Uterine carcinosarcomas (malignant mixed müllerian tumours): a review with special emphasis on the controversies in management. Obstetrics and Gynecology International, 2011, 470795. https://doi.org/10.1155/2011/470795
Gonzalez Bosquet, J., Terstriep, S. A., Cliby, W. A., Brown-Jones, M., Kaur, J. S., Podratz, K. C., & Keeney, G. L. (2010). The impact of multi-modal therapy on survival for uterine carcinosarcomas. Gynecologic oncology, 116(3), 419–423. https://doi.org/10.1016/j.ygyno.2009.10.053
D. Siva Ranjan, Malignant mixed mullerian tumor of the uterus (uterine carcinosarcoma): a case report https://doi.org/10.9790/3013-0309-49-52
Siva, R.D., Surendar, J., Rama, A.S. and Manjunatha, H.K. (2013) Malignant Mixed Mulleriantumor of the Uterus (Uterine Carcinosarcoma): A Case Report. IOSR Journal of Pharmacy, 3, 49-52. https://doi.org/10.9790/3013-0309-49-52
Ramondetta, L. M., Burke, T. W., Jhingran, A., Schmandt, R., Bevers, M. W., Wolf, J. K., Levenback, C. F., & Broaddus, R. (2003). A phase II trial of cisplatin, ifosfamide, and mesna in patients with advanced or recurrent uterine malignant mixed müllerian tumors with evaluation of potential molecular targets. Gynecologic oncology, 90(3), 529–536. https://doi.org/10.1016/s0090-8258(03)00332-9
Sutton, G., Kauderer, J., Carson, L. F., Lentz, S. S., Whitney, C. W., Gallion, H., & Gynecologic Oncology Group (2005). Adjuvant ifosfamide and cisplatin in patients with completely resected stage I or II carcinosarcomas (mixed mesodermal tumors) of the uterus: a Gynecologic Oncology Group study. Gynecologic oncology, 96(3), 630–634. https://doi.org/10.1016/j.ygyno.2004.11.022
Lee, T. Y., Lee, C., Choi, W. J., Lee, J. Y., & Kim, H. Y. (2013). Synchronous occurrence of primary malignant mixed müllerian tumor in ovary and uterus. Obstetrics & gynecology science, 56(4), 269–272. https://doi.org/10.5468/ogs.2013.56.4.269
McCluggage W. G. (2002). Malignant biphasic uterine tumors: carcinosarcomas or metaplastic carcinomas? Journal of Clinical Pathology, 55(5), 321–325. https://doi.org/10.1136/jcp.55.5.321
Kanthan, R., & Senger, L. (2010). Uterine Carcinosarcomas (Malignant Mixed Müllerian Tumours): A Review with Special Emphasis on the Controversies in Management. Obstetrics and Gynecology International, 2011(1), 470795. https://doi.org/10.1155/2011/470795
Rajshekar, S. K., Guruprasad, B., Shakunthala, P., Rathod, P., Devi, U., & Bafna, U. (2013). Malignant mixed Mullerian tumour of the uterus. Ecancermedicalscience, 7, 302. https://doi.org/10.3332/ecancer.2013.302
Duman, B. B., Kara, I. O., Günaldi, M., & Ercolak, V. (2011). Malignant mixed Mullerian tumor of the ovary with two cases and review of the literature. Archives of gynecology and obstetrics, 283(6), 1363–1368. https://doi.org/10.1007/s00404-011-1845-6
Callister, M., Ramondetta, L. M., Jhingran, A., Burke, T. W., & Eifel, P. J. (2004). Malignant mixed Müllerian tumors of the uterus: analysis of patterns of failure, prognostic factors, and treatment outcome. International journal of radiation oncology, biology, physics, 58(3), 786–796. https://doi.org/10.1016/S0360-3016(03)01561-X
Gupta, M., & Kiruthiga, K. G. (2015). Malignant mixed Mullerian tumour of uterus secondary to tamoxifen therapy for hormone responsive breast cancer. BMJ case reports 2015, bcr2015209981. https://doi.org/10.1136/bcr-2015-209981
Felix, A. S., Stone, R. A., Bowser, R., Chivukula, M., Edwards, R. P., Weissfeld, J. L., & Linkov, F. (2011). Comparison of survival outcomes between patients with malignant mixed mullerian tumors and high-grade endometrioid, clear cell, and papillary serous endometrial cancers. International journal of gynecological cancer: official journal of the International Gynecological Cancer Society, 21(5), 877–884. https://doi.org/10.1097/IGC.0b013e31821a62dd
Pezzicoli, G., Moscaritolo, F., Silvestris, E., Silvestris, F., Cormio, G., Porta, C., & D'Oronzo, S. (2021). Uterine carcinosarcoma: An overview. Critical reviews in oncology/hematology, 163, 103369. https://doi.org/10.1016/j.critrevonc.2021.103369
Raffone, A., Travaglino, A., Raimondo, D., Maletta, M., Vivo, V. D., Visiello, U., Casadio, P., Seracchioli, R., Zullo, F., Insabato, L., & Mollo, A. (2022). Uterine carcinosarcoma vs endometrial serous and clear cell carcinoma: A systematic review and meta-analysis of survival. International Journal of Gynecology & Obstetrics, 158(3), 520-527. https://doi.org/10.1002/ijgo.14033
Travaglino, A., Raffone, A., Raimondo, D., Arciuolo, D., Angelico, G., Valente, M., Scaglione, G., Casadio, P., Inzani, F., Mollo, A., Santoro, A., Seracchioli, R., & Zannoni, G. F. (2022). Prognostic value of the TCGA molecular classification in uterine carcinosarcoma. International Journal of Gynecology & Obstetrics, 158(1), 13-20. https://doi.org/10.1002/ijgo.13937

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.